New ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
An extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.
Pluripotent stem cell technology provider for drug discovery, Axol Bioscience Ltd (Axol), has signed an exclusive agreement...
The promise of immuno-oncology: An R&D perspective
Dr Robin Knight, CEO and co-founder, IN-PART, discusses emerging cancer immunotherapies.
Cancer immunotherapy, also referred to as immuno-oncology, is gaining traction. New treatments are becoming available all the time, and they’re showing incredible promise in...
90 years on, the time-bomb of antibiotic resistance
By Professor Colin Garner
The events of 28 September 1928 could justifiably lay claim to being called the most significant breakthrough in medical history.
With typical ingenuity and a quantity of genius, Sir Alexander Fleming discovered...
Pain or gain? How the brain chooses
Imagine having to choose over and over between what you enjoy doing and the pain that it might cause you, whether physical or emotional.
If you live with conditions such as depression, anxiety, or chronic...
Investment at the beating Heart
The life sciences industry represents one of the most successful economic sectors in the UK and its growth is an important part of the government’s Industrial Strategy.
An ageing population, a growing middle class and...
Rheumatology drugs study
Researchers at the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath, part of the Royal United Hospitals Bath NHS Foundation Trust, are celebrating recruiting the first patient globally to an international study that...
The baby brain scans that could help predict symptoms of autism and ADHD
London researchers are embarking on a three-year study aiming to identify babies at higher than average risk of autism spectrum conditions (ASC) and attention deficit hyperactivity disorder (ADHD).
The work at King’s College London is...
Patient recruitment: The balancing act
Well conducted patient and public engagement can have a positive impact on recruitment and retention. To really increase your chances of success you need to be engaging patients as early as possible in the...
How different funding models are driving research towards commercialisation
Taking innovation forward can be a complex process, and university commercialisation offices help academics with specialist support to bring their research to market.
UCL Business (UCLB) is a leading commercialisation office and a part of...
Having access to finance is an essential ingredient to grow and prosper
Graeme Fisher: Managing Director for Communications and Policy at British Business Bank
Smaller businesses are a fundamental part of the UK economy, driving growth and employment creation. Those businesses categorised as small and medium-sized enterprises (SMEs)...
Smarter Insulated Packaging
From chilled food products to temperature sensitive pharmaceuticals, wool is at the heart of a revolution in the insulated packaging being used for temperature controlled logistics. Significantly, it’s not just the pressures to find...
Creating a Corona Vaccine
Varuni Paranavitane, IP Solicitor, AA Thornton.
As the world faces unprecedented challenges caused by the SARS-Cov-2 virus, we look at the science behind vaccine technology being investigated and how intellectual property rights may play a part...
Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...
Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO
Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...
Vericel: Improving multicellular therapy through advanced manufacturing
Founded in 1989, Vericel (formerly Aastrom Biosciences) is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.
The company currently markets two cell...
Potential breakthrough in treatment of rare disease
Biotech company Actigen has initiated a clinical development programme for GNR-055, a potentially breakthrough treatment for the life-limiting, rare disease mucopolysaccharidosis II (MPS II) (also known as Hunter syndrome). Occurring in around 1 in...
Nominations now open for the 2014 biomedical awards
Bionow is urging companies and individuals across the North of England to nominate their outstanding achievements for the prestigious 2014 Biomedical Awards.
The Awards, now in its 2nd year will take place on Thursday 24...